Replies to post #160854 on Biotech Values

[mcbio]

ARIA

No love for Ariad here on BV? Pretty nice start for Ponatinib, especially in light of the fact that it is a dirty drug, with a bad AE profile and a high discontinuation rate.

$3B+ market cap keeps me away, for better or worse.